Are current pharmacotherapeutic strategies effective in treating OCD?

References

• Fontenelle LF, Mendlowicz MV, Versiani M. The descriptive epidemiology of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:327–337.
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental Health (UK). Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder [Internet]. Leicester (UK): British Psychological Society; 2006 [cited 2013 Sep 20]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK56458/
   Google Scholar
• Skapinakis P, Caldwell DM, Hollingworth W, et al. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2016;3:730–739.
   PubMed Web of Science ®Google Scholar
• Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002;22:309–317.
   PubMed Web of Science ®Google Scholar
• Geller DA, Biederman J, Stewart SE, et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry. 2003;160:1919–1928.
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Reghunandanan S, Brown A, et al. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. Aust N Z J Psychiatry. 2013;47:121–141.
   PubMed Web of Science ®Google Scholar
• Sharma E, Thennarasu K, Reddy YCJ. Long-term outcome of obsessive-compulsive disorder in adults: a meta-analysis. J Clin Psychiatry. 2014;75:1019–1027.
   PubMed Web of Science ®Google Scholar
• Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005;162:151–161.
   PubMed Web of Science ®Google Scholar
• Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol. 2002;5:181–191.
   PubMed Web of Science ®Google Scholar
• Hazari N, Narayanaswamy JC, Arumugham SS. Predictors of response to serotonin reuptake inhibitors in obsessive-compulsive disorder. Expert Rev Neurother. 2016;16:1–17.
   PubMed Web of Science ®Google Scholar
• Soomro GM, Altman D, Rajagopal S, et al. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;23:CD001765.
   PubMed Web of Science ®Google Scholar
• Cherian AV, Math SB, Kandavel T, et al. A 5-year prospective follow-up study of patients with obsessive-compulsive disorder treated with serotonin reuptake inhibitors. J Affect Disord. 2014;152–154:387–394.
   PubMed Web of Science ®Google Scholar
• Albert U, Aguglia E, Maina G, et al. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry. 2002;63:1004–1009.
   PubMed Web of Science ®Google Scholar
• Denys D, van der Wee N, Hjgm VM, et al. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol. 2003;23:568–575.
   PubMed Web of Science ®Google Scholar
• Balachander S, Kodancha PG, Arumugham SS, et al. Effectiveness of venlafaxine in selective serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: experience from a specialty clinic in India. J Clin Psychopharmacol. 2019;39:82–85.
   PubMed Web of Science ®Google Scholar
• Veale D, Miles S, Smallcombe N, et al. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2014;14:317.
   PubMed Web of Science ®Google Scholar
• Dold M, Aigner M, Lanzenberger R, et al. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2015; 18:1–11.
   Web of Science ®Google Scholar
• Zhou -D-D, Zhou -X-X, Li Y, et al. Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: a network meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2019;90:277–287.
   PubMed Web of Science ®Google Scholar
• Simpson HB, Foa EB, Liebowitz MR, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013;70:1190–1199.
   PubMed Web of Science ®Google Scholar
• Hegde A, Kalyani BG, Arumugham SS, et al. Effectiveness of risperidone augmentation in obsessive-compulsive disorder: experience from a specialty clinic in India. J Clin Psychopharmacol. 2016;36:381–384.
   PubMed Web of Science ®Google Scholar
• Hegde A, Kalyani BG, Arumugham SS, et al. Aripiprazole augmentation in highly treatment-resistant obsessive-compulsive disorder – experience from a specialty clinic in India. Int J Psychiatry Clin Pract. 2016;21:1–3.
   PubMed Web of Science ®Google Scholar
• Schirmbeck F, Zink M. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol. 2012;10:88–95.
   PubMed Web of Science ®Google Scholar
• Sheshachala K, Narayanaswamy JC. Glutamatergic augmentation strategies in obsessive–compulsive disorder. Indian J Psychiatry. 2019;61:S58–S65.
   PubMed Web of Science ®Google Scholar
• Farnia V, Gharehbaghi H, Alikhani M, et al. Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: double-blind, randomized, placebo-controlled trial. J Psychiatr Res. 2018;104:137–143.
   PubMed Web of Science ®Google Scholar
• Stein DJ, Costa DLC, Lochner C, et al. Obsessive–compulsive disorder. Nat Rev Dis Primers. 2019;5:1–21.
   PubMed Web of Science ®Google Scholar
• Albert U, Marazziti D, Di Salvo G, et al. A systematic review of evidence-based treatment strategies for obsessive-compulsive disorder resistant to first-line pharmacotherapy. Curr Med Chem. 2018;25:5647–5661.
   PubMed Web of Science ®Google Scholar
• P-c B, Bittner N, Holling H, et al. D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: a meta-analysis. Plos One. 2017;12:e0173660.
   PubMed Web of Science ®Google Scholar
• Andrade C. Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder. J Clin Psychiatry. 2015;76:e72–75.
   PubMed Web of Science ®Google Scholar
• Sharafkhah M, Aghakarim Alamdar M, Massoudifar A, et al. Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study. Int Clin Psychopharmacol. 2019;34:222–233.
   PubMed Web of Science ®Google Scholar
• Kalyani BG, Hegde A, Arumugham SS, et al. Is ondansetron augmentation effective in obsessive-compulsive disorder? J Clin Psychopharmacol. 2017;37:380–381.
   PubMed Web of Science ®Google Scholar
• Marazziti D, Mucci F, Fontenelle LF. Immune system and obsessive-compulsive disorder. Psychoneuroendocrinology. 2018;93:39–44.
   PubMed Web of Science ®Google Scholar
• da Conceição Costa DL, Shavitt RG, Castro Cesar RC, et al. Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making. J Psychiatr Res. 2013;47:1700–1707.
   PubMed Web of Science ®Google Scholar
• Eddy KT, Dutra L, Bradley R, et al. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004;24:1011–1030.
   PubMed Web of Science ®Google Scholar
• Rapinesi C, Kotzalidis GD, Ferracuti S, et al. Brain stimulation in obsessive-compulsive disorder (OCD): a systematic review. Curr Neuropharmacol. 2019;17:787–807.
   PubMed Web of Science ®Google Scholar
• Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract. 2004;17:59–67.
   PubMedGoogle Scholar